Lilly Eli & Co Sentiment Worsening on Bad Stock Potential, Now at 0.78

June 27, 2018 - By Matthew Medley

Eli Lilly and Company (NYSE:LLY) Corporate Logo

Lilly Eli & Co’s Sentiment

“Big money sentiment for Lilly Eli & Co (NYSE:LLY) in 2018 Q1 decreased to 0.78, according to SEC.gov filings. So its down -0.32, from 2017Q4’s 1.1. 390 investment professionals opened new and increased holdings, while 503 decreased and sold their positions in Lilly Eli & Co so the sentiment turned negative. These funds own 810.94 million shares, that’s down from 827.08 million shares in 2017Q4. Funds holding Lilly Eli & Co in top 10 increased from 15 to 16 for an increase of 1. In total 76 funds closed positions, 427 reduced and 308 increased. Also 82 funds bought new Lilly Eli & Co stakes.

Biggest Lilly Eli & Co Investors

As of 2018 Q1 Lilly Endowment Inc has 100% invested in Lilly Eli & Co. As of 2018 Q1, 385,549 shares of Lilly Eli & Co are owned by Private Capital Advisors Inc.. In addition, Weatherly Asset Management L. P. reported 327,650 shares in Lilly Eli & Co equivalent to 6.01% of its US equity exposure. Valueworks Llc revealed 70,615 shares position in Lilly Eli & Co. The New York-based fund Sio Capital Management Llc holds 82,363 shares or 3.83% of their US equity exposure.

Eli Lilly and Company discovers, develops, makes, and markets pharmaceutical products worldwide.The company has $86.86 billion market cap. It operates through two divisions, Human Pharmaceutical Products and Animal Health Products.79.53 is the P/E ratio. The firm offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency.

LLY hit $85.1 during the last trading session after $0.67 change.Currently Eli Lilly and Company is uptrending after 5.65% change in last June 27, 2017. LLY has also 2.83M shares volume. LLY underperformed by 6.92% the S&P500.

Eli Lilly and Company (NYSE:LLY)’s quarterly earnings will be published on July, 24., according to RTT. Analysts predict $1.34 EPS, which is $0.23 up or 20.72 % from 2017’s $1.11 EPS. If $1.34 is reported, LLY’s profit will hit $1.37 billion for 15.88 P/E. After $1.34 EPS was published last quarter, analysts now see EPS growth of 0.00 % for Eli Lilly and Company.

Fil has 0.09% invested in Eli Lilly and Company (NYSE:LLY). Alliancebernstein Limited Partnership invested in 0.17% or 3.04M shs. Northcoast Asset Mgmt Limited Liability has 0.23% invested in Eli Lilly and Company (NYSE:LLY). Gfs Advsrs Lc owns 0.08% invested in Eli Lilly and Company (NYSE:LLY) for 5,000 shs. Taurus Asset Management Limited Liability Company reported 3,295 shs. Washington Tru Bancorp holds 12,587 shs or 0.14% of its capital. Stock Yards Bankshares And Trust owns 39,029 shs for 0.34% of their capital. Sawgrass Asset Mgmt Ltd Liability Corp has invested 0.02% in Eli Lilly and Company (NYSE:LLY). Cap Fund Mgmt Sa invested in 51,382 shs or 0.02% of the stock. Wealthtrust Axiom Limited Liability Company holds 0.75% of its capital in Eli Lilly and Company (NYSE:LLY) for 26,523 shs. Rodgers Brothers holds 93,820 shs. Destination Wealth Mgmt holds 0% or 103 shs in its capital. Lincoln National Corporation accumulated 5,024 shs. Dimensional Fund Advsr L P stated it has 0.06% in Eli Lilly and Company (NYSE:LLY). X Mngmt Limited Liability Company reported 0.03% of its capital in Eli Lilly and Company (NYSE:LLY).

Eli Lilly and Company registered $92.69 million net activity with 1 insider buy and 19 insider sales since February 1, 2018. Mahony Susan also sold $1.81M worth of Eli Lilly and Company (NYSE:LLY) on Friday, April 13. On Wednesday, June 13 the insider LILLY ENDOWMENT INC sold $957,953. Shaw Christi sold $691,775 worth of Eli Lilly and Company (NYSE:LLY) or 8,426 shs on Tuesday, May 29. The insider Zakrowski Donald A sold $67,934. 25,000 shs valued at $2.13M were sold by Conterno Enrique A on Thursday, May 31. 9,027 shs were sold by Simmons Jeffrey N, worth $708,620.

Eli Lilly and Company (NYSE:LLY) Ratings Coverage

In total 12 analysts cover Eli Lilly (NYSE:LLY). “Buy” rating has 6, “Sell” are 1, while 5 are “Hold”. (NYSE:LLY) has 50% bullish analysts. With $105.0 highest and $74 lowest PT, Eli Lilly has $92.11 average PT or 8.24% above the current ($85.1) price. 19 are the (NYSE:LLY)’s ratings reports on 27 Jun 2018 according to StockzIntelligence Inc. In Monday, February 26 report Jefferies maintained the stock with “Buy” rating. In Tuesday, January 16 report Goldman Sachs downgraded the stock to “Hold” rating. The stock rating was maintained by Credit Suisse with “Underperform” on Thursday, June 21. On Friday, January 5 the firm has “Buy” rating given by Argus Research. On Thursday, February 1 the firm has “Underperform” rating given by BMO Capital Markets. On Thursday, February 1 the stock has “Hold” rating by Leerink Swann. On Thursday, June 7 Cantor Fitzgerald initiated Eli Lilly and Company (NYSE:LLY) with “Buy” rating. On Friday, April 13 the stock has “Market Perform” rating by BMO Capital Markets. The stock rating was maintained by BMO Capital Markets with “Market Perform” on Wednesday, April 25. On Monday, June 11 the stock has “Buy” rating by J.P. Morgan.

For more Eli Lilly and Company (NYSE:LLY) news posted briefly go to: Streetinsider.com, Streetinsider.com, Streetinsider.com, Fool.com or Fool.com. The titles are as follows: “Eli Lilly & Co. (LLY) Highlights New Data from Three Phase 1b Studies Evaluating URLi Compared to Humalog” posted on June 25, 2018, “Eli Lilly & Co. (LLY) Highlights Promise of Once-Weekly Trulicity (dulaglutide) in Data from Phase 2 study” on June 25, 2018, “Boehringer Ingelheim, Lilly (LLY) Announce Phase III for Empagliflozin as Adjunct to Insulin in Type 1 Diabetes Met …” with a publish date: June 25, 2018, “Better Buy: Johnson & Johnson vs. Eli Lilly” and the last “Is Pfizer’s Lead Growth Driver in Trouble?” with publication date: June 26, 2018.

Eli Lilly and Company (NYSE:LLY) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.